Literature DB >> 18008168

Exploiting cholera vaccines as a versatile antigen delivery platform.

Anisia J Silva1, Francis O Eko, Jorge A Benitez.   

Abstract

The development of safe, immunogenic and protective cholera vaccine candidates makes possible their use as a versatile antigen delivery platform. Foreign antigens can be delivered to the immune system with cholera vaccines by expressing heterologous antigens in live attenuated vectors, as fusion proteins with cholera toxin subunits combined with inactivated Vibrio cholerae whole cells or by exposing them on the surface of V. cholerae ghosts. Progress in our understanding of the genes expressed by V. cholerae during infection creates unprecedented opportunities to develop an improved generation of vaccine vectors to induce immune protection against a broad range of pathogenic organisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18008168      PMCID: PMC2753531          DOI: 10.1007/s10529-007-9594-0

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  71 in total

Review 1.  New strategies for combination vaccines based on the extended recombinant bacterial ghost system.

Authors:  F O Eko; A Witte; V Huter; B Kuen; S Fürst-Ladani; A Haslberger; A Katinger; A Hensel; M P Szostak; S Resch; H Mader; P Raza; E Brand; J Marchart; W Jechlinger; W Haidinger; W Lubitz
Journal:  Vaccine       Date:  1999-03-26       Impact factor: 3.641

Review 2.  In vivo induced antigen technology (IVIAT).

Authors:  Sean M Rollins; Amanda Peppercorn; Long Hang; Jeffrey D Hillman; Stephen B Calderwood; Martin Handfield; Edward T Ryan
Journal:  Cell Microbiol       Date:  2005-01       Impact factor: 3.715

3.  Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh.

Authors:  Firdausi Qadri; Mohiul I Chowdhury; Shah M Faruque; Mohammed A Salam; Tanvir Ahmed; Yasmin A Begum; Amit Saha; Mohammed S Alam; K Zaman; Lorenz V Seidlein; Eunsik Park; Kevin P Killeen; John J Mekalanos; John D Clemens; David A Sack
Journal:  J Infect Dis       Date:  2005-07-15       Impact factor: 5.226

4.  Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.

Authors:  D D Trach; J D Clemens; N T Ke; H T Thuy; N D Son; D G Canh; P V Hang; M R Rao
Journal:  Lancet       Date:  1997-01-25       Impact factor: 79.321

5.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.

Authors:  E T Ryan; J R Butterton; R N Smith; P A Carroll; T I Crean; S B Calderwood
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Second-generation recombination-based in vivo expression technology for large-scale screening for Vibrio cholerae genes induced during infection of the mouse small intestine.

Authors:  C G Osorio; J A Crawford; J Michalski; H Martinez-Wilson; J B Kaper; A Camilli
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

7.  The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.

Authors:  Luis García; Manuel Díaz Jidy; Hilda García; Boris L Rodríguez; Roberto Fernández; Gemma Año; Bárbara Cedré; Tania Valmaseda; Edith Suzarte; Margarita Ramírez; Yadira Pino; Javier Campos; Jorge Menéndez; Rodrigo Valera; Daniel González; Irma González; Oliver Pérez; Teresita Serrano; Miriam Lastre; Fernando Miralles; Judith Del Campo; Jorge Luis Maestre; José Luis Pérez; Arturo Talavera; Antonio Pérez; Karen Marrero; Talena Ledón; Rafael Fando
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

8.  Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains.

Authors:  J R Butterton; E T Ryan; D W Acheson; S B Calderwood
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

9.  Th1-type immune response to a Coccidioides immitis antigen delivered by an attenuated strain of the non-invasive enteropathogen Vibrio cholerae.

Authors:  Anisia J Silva; Jorge A Benitez
Journal:  FEMS Immunol Med Microbiol       Date:  2005-03-01

10.  In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae.

Authors:  E T Ryan; T I Crean; M John; J R Butterton; J D Clements; S B Calderwood
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

View more
  4 in total

1.  Attenuation of bacterial virulence by quorum sensing-regulated lysis.

Authors:  Anisia J Silva; Jorge A Benitez; Jian-He Wu
Journal:  J Biotechnol       Date:  2010-07-29       Impact factor: 3.307

2.  A Self-Assembling Whole-Cell Vaccine Antigen Presentation Platform.

Authors:  Julie Liao; Daniel R Smith; Jóhanna Brynjarsdóttir; Paula I Watnick
Journal:  J Bacteriol       Date:  2018-07-10       Impact factor: 3.490

3.  Use of stabilized luciferase-expressing plasmids to examine in vivo-induced promoters in the Vibrio cholerae vaccine strain CVD 103-HgR.

Authors:  Cara E Morin; James B Kaper
Journal:  FEMS Immunol Med Microbiol       Date:  2009-07-01

Review 4.  Live bacterial vaccine vectors: an overview.

Authors:  Adilson José da Silva; Teresa Cristina Zangirolami; Maria Teresa Marques Novo-Mansur; Roberto de Campos Giordano; Elizabeth Angélica Leme Martins
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.